Maraviroc
94 interactions 1 explained in plain English 343 cited referencesMaraviroc is used along with other medications to treat a certain type of human immunodeficiency virus (HIV) infection in adults and children who weigh at least 4.4 lb (2 kg). Maraviroc is in a class of medications called HIV entry and fusion inhibitors. It works by decreasing the amount of HIV in the blood. Although m… Read the full Maraviroc drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Maraviroc Idelalisib Zydelig Increased maraviroc exposure Details Maraviroc Indinavir Increased maraviroc exposure Details Maraviroc Itraconazole Sporanox Increased maraviroc exposure Details Maraviroc Ivosidenib Tibsovo Reduced maraviroc exposure and risk of loss of efficacy Details Maraviroc Ketoconazole Extina Increased maraviroc exposure and an increased maraviroc-related adverse reactions Details Maraviroc Larotrectinib Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Maraviroc Lenacapavir Sunlenca Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Maraviroc Letermovir Prevymis Increased CYP3A substrate exposure Details Maraviroc Lonafarnib Zokinvy Increased maraviroc exposure Details Maraviroc Lumacaftor Reduced maraviroc exposure Details Maraviroc Mifepristone Korlym Increased maraviroc exposure Details Maraviroc Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Maraviroc Mitotane Lysodren Reduced maraviroc exposure Details Maraviroc Nefazodone Increased maraviroc exposure Details Maraviroc Nelfinavir Viracept Increased maraviroc exposure Details Maraviroc Netupitant Increased exposure of CYP3A4 substrate Details Maraviroc Nirmatrelvir Increased maraviroc exposure Details Maraviroc Olutasidenib Rezlidhia Reduced sensitive CYP3A substrate exposure Details Maraviroc Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Maraviroc Paritaprevir Increased maraviroc exposure Details Maraviroc Pexidartinib Turalio Hepatotoxicity Details Maraviroc Phenytoin Dilantin Reduced maraviroc exposure Details Maraviroc Pirtobrutinib Jaypirca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Maraviroc Posaconazole Noxafil Increased maraviroc exposure Details Maraviroc Ranolazine Aspruzyo Increased exposure of CYP3A4 substrate Details Maraviroc Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Maraviroc Ribociclib Kisqali Increased maraviroc exposure Details Maraviroc Rifampin Rifadin Reduced maraviroc exposure Details Maraviroc Rifapentine Priftin Reduced maraviroc exposure Details Maraviroc Ritlecitinib Litfulo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Maraviroc Ritonavir Norvir Increased maraviroc exposure Details Maraviroc Saquinavir Increased maraviroc exposure Details Maraviroc St John's Wort Reduced maraviroc exposure resulting in suboptimal levels of maraviroc that lead to loss of virologic response and possible resist... Details Maraviroc Suzetrigine Journavx Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Maraviroc Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Maraviroc Telaprevir Increased maraviroc exposure Details Maraviroc Telithromycin Increased maraviroc exposure Details Maraviroc Trofinetide Daybue Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Maraviroc Troleandomycin Increased maraviroc exposure Details Maraviroc Tucatinib Tukysa Increased maraviroc exposure DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist